All articles tagged with #niclosamide
A new study in Advanced Healthcare Materials reports that a modified version of the anti-parasitic drug niclosamide, delivered via a specialized nanocarrier, reduced lesion growth and pain sensitivity in mice with endometriosis. While the therapy remains in preclinical stages, it offers a potential non-hormonal alternative to current treatments that often fail to provide long-term relief.
Researchers at Washington State University have developed a nanotherapy that delivers the anti-parasitic drug niclosamide directly to immune cells associated with endometriosis. In mouse models, this approach reduced lesion growth and pain symptoms after a single dose, offering a potential non-hormonal alternative to current treatments. The study addresses the limitations of oral niclosamide, which has poor solubility and causes side effects, by using a dendrimer nanocarrier to target specific macrophages. While promising, the therapy remains in the preclinical stage, with human trials and FDA approval potentially taking five years or more.